PPT-Tailoring Statin Therapy in Women

UnderRepresentation of Women in Clinical Trials CVD in Women Women s CV Risk is Often Misunderstood or Misdiagnosed Gender Disparities in Screening Diagnosis and Treatment of Dyslipidemia. Louis H. Stein, Jessica Berger, Maryann . Tranquilli. , . John A. . Elefteriades. .. . The Aortic Institute at Yale – New Haven Hospital . Bench top to bedside interaction. . Medial Degeneration . Optimizing . patient care. William Cromwell, MD, FAHA, FNLA. Chief Medical Officer – LipoScience, Inc.. Chief – Lipoprotein and Metabolic Disorders Institute. Adjunct Associate Professor – Wake Forest University School of Medicine. Beauty is in the Eye of the Beholder. Brian Asbill, MD. Asheville Cardiology Associates. Overview. NHLBI, ACC, AHA expert panel convened 2008. First new guidelines since ATP III guideline update in . Evidence from . meta-analyses of . Mendelian. . randomization. studies. , . prospective. cohort studies. , . and. . randomized. . controlled. trials . unequivocally establishes that LDL causes ASCVD. Recommendations for Patient-Centered Management of Dyslipidemia Part 2: Women’s Health. Jacobson ta, et al. Journal of clinical . lipidology. Doi. : 10.1016/jacl.2015.09.002. National Lipid Association. Control. Relative risk. Absolute Effect. (per thousand). Statin. Myalgia. 348/14960. (2.3%) . 288/14520. (2.0%). 1.02. (0.88-1.19). +1. (-1 to +5). Rhabdomyolysis. 138/2454. (5.6%). 158/2446. (6.5%). of the NLA. Conclusions of the NLA Safety Task Force for Muscle Safety. Myopathy and rhabdomyolysis are associated with statin therapy, as a class effect. Elevated creatine kinase (CK) levels may indicate statin-induced muscle damage. Quality Department Guidelines for Clinical Care Ambulatory Lipid TherapyGuideline TeamTeam LeaderAudrey LFan, MDGeneral MedicineTeam MembersJill NFenske, MDFamily MedicineVan Harrison, PhDMedical Educ Which ONE of the following statements regarding the mechanism of action of PCSK9 inhibitors is CORRECT?. a. Reduced hepatic production of LDL-C by inhibition of ATP citrate lyase. b. Increased LDL receptor (LDLR) surface density via increase in LDLR recycling and reduced LDLR degradation. to Reduce Atherosclerotic Cardiovascular . Risk in Adults . 2013 ACC/AHA Guideline on. O. verview. RCTs indicated a constant reduction of ASCVD by . statins. in 1ry & 2ry prevention.. No event reduction. of. Dyslipidemia. Navid Saadat, MD. Associate Professor of Endocrinology. Shahid Beheshti University of Medical Sciences. Rationale for . Treatment. Benefit . of . LDL-C. . reduction in . CVD events. atherosclerosis. . in non-infarct . related . coronary arteries: . a serial intravascular ultrasonography study . IBIS-4 (Integrated Biomarkers . and. Imaging Study). Lorenz Räber. , Masanori Taniwaki, Serge Zaugg. Sex . Male. Diabetes. . History. T2D, . onset. @45 . yrs. , treatment: . metformin. , . sitagliptin. and . gliclazide. . Organ. . damage. . evaluation. :. Eyes. : No . signs. of . retinopathy. Risk Assessment and Cholesterol Management. Roger S. Blumenthal, MD. The Kenneth Jay . Pollin. Professor of Cardiology. Director, Johns Hopkins Ciccarone Center for the Prevention of Heart Disease.